CU was first described by Duke in 1924. The term cholinergic is derived from the finding that hives similar to those of CU can be evoked using cholinergic agonists (e.g. methacholine).
CU typically presents with a number of small, short-lasting hives but may also involve cutaneous inflammation (wheals) and pain which develops usually in response to exercise, bathing, staying in a heated environment, or emotional stress. Although the symptoms subside rapidly, commonly within 1 hour, CU may significantly impair quality of life, especially in relation to sporting and sexual activities.
Though overall research is limited, various studies indicate that CU is relatively common across populations with prevalence rates reportedly ranging from 5% to 20% (depending on locale, race, and age). The condition is more common in young adults, and prevalence appears to peak in adult aged 26–28 (up to 20%). The vast majority of cases are reported to be mild, and proportionally few individuals seek medical attention regarding the condition.
This subtype of CU refers to those who are hypersensitive to their own sweat.
A positive reaction to an intradermal injection of autologous sweat.
The hives are observed to coincide with perspiration points of sweating.
Tanaka et al. found that the sweat hyper-sensitivities of CU and atopic dermatitis seem to be virtually the same, and therefore, the sweat-induced histamine release from basophils may also be mediated by a specific IgE for sweat in atopic dermatitis as well as CU.
Proposed first-line treatment: Rapid desensitization protocol using autologous sweat.
Non-pharmacological treatment: Forced perspiration by excessive body warming (hot bath or exercise) used daily may reduce the symptoms through exhaustion of inflammatory mediators. This non-pharmacological treatment is contraindicated in those with CU as a result of hypohidrosis (see below).
Antihistamines are a commonly prescribed first-line treatment for conventional urticaria, but its effectiveness in the treatment of CU is rather limited in most cases.
This subtype of CU refers to those who have abnormally reduced sweating.
Sweat is readily visualized by a topical indicator such as iodinated starch or sodium alizarin sulphonate. Both undergo a dramatic colour change when moistened by sweat. A thermoregulatory sweat test evaluates the body’s response to a thermal stimulus by inducing sweating through the use of a hot box ⁄ room, thermal blanket or exercise. Failure of the topical indicator to undergo a colour change during thermoregulatory sweat testing can indicate anhidrosis and/or hypohidrosis (see minor test).
A skin biopsy may reveal cellular infiltrates in sweat glands or ducts.
Severe heat intolerance (e.g., nausea, dizziness, and headache), and tingling, pricking, or burning pain over the entire body on exposure to hot environments or prolonged exercise which improve after cooling the body. Occurs in the absence of any causative skin, metabolic, or neurological disorders.
Diagram visualizing the overflow of acetylcholine to adjacent mast cells.
The wheals, hypohidrosis, and pain seems to result from the low expression levels of acetylcholinesterase (AchE) and cholinergic receptor, muscarinic 3 (CHRM3) in the eccrine gland epithelial cells.
Elevated expression levels of CCL2/MCP-1, CCL5/RANTES and CCL17/TARC which result in chemoattracted CD4+ and CD8+ T cell populations to the surrounding area may be responsible for exerting a downmodulatory effect on the AchE and CHRM3 expressions.
Corticosteroid inhibits the expressions of CCL2/MCP-1, CCL5/RANTES and CCL17/TARC. This further support the notion that CCL2/MCP-1, CCL5/RANTES and CCL17/TARC play a crucial role.
Non-pharmacological treatment: In the absence of sweat, cold-water sprays and wet towels can be used increase the evaporative loss of heat from the skin. Shifting to a cooler or air-conditioned environments when necessary can also reduce discomfort. In the event of severe hyperthermia (body temperature >106 °F/41 °C), drastic measures such as immersion in ice-cold water are necessary to prevent irreversible brain damage.
Unknown or unclassified at this time. Representing those who do not fall under any of the above categories.
^ abNakamizo, S.; Egawa, G.; Miyachi, Y.; Kabashima, K. (2012). "Cholinergic urticaria: Pathogenesis-based categorization and its treatment options". Journal of the European Academy of Dermatology and Venereology26 (1): 114–116. doi:10.1111/j.1468-3083.2011.04017.x. PMID21371134.
^DDuke, W. W. (1924). "URTICARIA CAUSED SPECIFICALLY BY THE ACTION OF PHYSICAL AGENTS<subtitle>(LIGHT, COLD, HEAT, FREEZING, BURNS, MECHANICAL IRRITATION, AND PHYSICAL AND MENTAL EXERTION)</subtitle>". JAMA: the Journal of the American Medical Association83: 3–1. doi:10.1001/jama.1924.02660010007002.edit
^Hirschmann, J. V.; Lawlor, F.; English, J. S.; Louback, J. B.; Winkelmann, R. K.; Greaves, M. W. (1987). "Cholinergic urticaria. A clinical and histologic study". Archives of dermatology123 (4): 462–467. doi:10.1001/archderm.1987.01660280064024. PMID3827277.
^Poon, E.; Seed, P. T.; Greaves, M. W.; Kobza-Black, A. (1999). "The extent and nature of disability in different urticarial conditions". The British journal of dermatology140 (4): 667–671. doi:10.1046/j.1365-2133.1999.02767.x. PMID10233318.
^ abZuberbier, T.; Althaus, C.; Chantraine-Hess, S.; Czarnetzki, B. M. (1994). "Prevalence of cholinergic urticaria in young adults". Journal of the American Academy of Dermatology31 (6): 978–981. doi:10.1016/S0190-9622(94)70267-5. PMID7962780.
^Silpa-Archa, N.; Kulthanan, K.; Pinkaew, S. (2011). "Physical urticaria: Prevalence, type and natural course in a tropical country". Journal of the European Academy of Dermatology and Venereology25 (10): 1194–1199. doi:10.1111/j.1468-3083.2010.03951.x. PMID21175877.
^ abKozaru, T.; Fukunaga, A.; Taguchi, K.; Ogura, K.; Nagano, T.; Oka, M.; Horikawa, T.; Nishigori, C. (2011). "Rapid Desensitization with Autologous Sweat in Cholinergic Urticaria". Allergology International60 (3): 277–281. doi:10.2332/allergolint.10-OA-0269. PMID21364312.
^ abcBito, T.; Sawada, Y.; Tokura, Y. (2012). "Pathogenesis of cholinergic urticaria in relation to sweating". Allergology international : official journal of the Japanese Society of Allergology61 (4): 539–544. doi:10.2332/allergolint.12-RAI-0485. PMID23093795.
^Kobayashi, H.; Aiba, S.; Yamagishi, T.; Tanita, M.; Hara, M.; Saito, H.; Tagami, H. (2002). "Cholinergic urticaria, a new pathogenic concept: Hypohidrosis due to interference with the delivery of sweat to the skin surface". Dermatology (Basel, Switzerland)204 (3): 173–178. PMID12037443.
^La Shell, M. S.; England, R. W. (2006). "Severe refractory cholinergic urticaria treated with danazol". Journal of drugs in dermatology : JDD5 (7): 664–667. PMID16865874.
^Pachor, M. L.; Lunardi, C.; Nicolis, F.; Cortina, P.; Accordini, C.; Marchi, G.; Corrocher, R.; De Sandre, G. (1987). "Usefulness of propranolol in the treatment of cholinergic urticaria". La Clinica terapeutica120 (3): 205–210. PMID2973859.
^Chia, K. Y.; Tey, H. L. (2012). "Approach to hypohidrosis". Journal of the European Academy of Dermatology and Venereology27 (7): 799–804. doi:10.1111/jdv.12014. PMID23094789.
^ abNakazato, Y.; Tamura, N.; Ohkuma, A.; Yoshimaru, K.; Shimazu, K. (2004). "Idiopathic pure sudomotor failure: Anhidrosis due to deficits in cholinergic transmission". Neurology63 (8): 1476–1480. PMID15505168.
^Sawada, Y.; Nakamura, M.; Bito, T.; Sakabe, J. I.; Kabashima-Kubo, R.; Hino, R.; Kobayashi, M.; Tokura, Y. (2013). "Decreased Expression of Acetylcholine Esterase in Cholinergic Urticaria with Hypohidrosis or Anhidrosis". Journal of Investigative Dermatology. doi:10.1038/jid.2013.244. PMID23748235.
^Ohshima, Y.; Yanagishita, T.; Ito, K.; Tamada, Y.; Nishimura, N.; Inukai, Y.; Iwase, S.; Sugenoya, J.; Watanabe, D. (2012). "Treatment of patients with acquired idiopathic generalized anhidrosis". British Journal of Dermatology168 (2): 430–432. doi:10.1111/j.1365-2133.2012.11112.x. PMID22709381.
^Thami, G. P.; Kaur, S.; Kanwar, A. J. (2003). "Acquired idiopathic generalized anhidrosis: A rare cause of heat intolerance". Clinical and experimental dermatology28 (3): 262–264. PMID12780708.